Arcturus Therapeutics Holdings Inc. (ARCT) |
|
24.59 -0.72 (-2.84%)
|
01-21 18:02 |
|
Open: |
24.99 |
Pre. Close: |
25.31 |
|
High:
|
26.25 |
Low:
|
24.5883 |
|
Volume:
|
516,492 |
Market Cap:
|
648M |
|
|
|
|
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
26.289 - 26.473 |
26.473 - 26.614 |
|
Low:
|
24.128 - 24.368 |
24.368 - 24.551 |
|
Close:
|
24.262 - 24.583 |
24.583 - 24.829 |
|
Technical analysis |
as of: 2022-01-21 4:24:49 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
| Target: |
Six months: 46.16  One year: 56.94 |
| Support: |
Support1: 24.59 Support2: 20.46 |
| Resistance: |
Resistance1: 39.52 Resistance2: 48.75 |
| Pivot: |
32.47 |
| Moving Average: |
MA(5): 27.45 MA(20): 34.19
MA(100): 42.03 MA(250): 42.63 |
| MACD: |
MACD(12,26): -3.41 Signal(9): -2.24 |
| Stochastic oscillator: |
%K(14,3): 1.12 %D(3): 4.47 |
| RSI: |
RSI(14): 27.97 |
| 52-week: |
High: 89.18 Low: 24.59 Change(%): -63.4 |
| Average Vol(K): |
3-Month: 618 10-Days: 483 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.ARCT has closed above bottom band by 6.1%. Bollinger Bands are 57.8% wider than normal. The large width of the bands suggest high volatility as compared to Arcturus Therapeutics Holdings Inc.'s normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Wed, 12 Jan 2022
$12.90 Million in Sales Expected for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) This Quarter - MarketBeat
Wed, 05 Jan 2022
Arcturus Therapeutics Holdings Inc. Expected to Earn FY2026 Earnings of $62.40 Per Share (NASDAQ:ARCT) - MarketBeat
Tue, 04 Jan 2022
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Sat, 25 Dec 2021
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has Debt But No Earnings; Should You Worry? - Nasdaq
Thu, 18 Nov 2021
Is Arcturus Therapeutics Holdings Inc (ARCT) a Good Buy in the Biotechnology Industry? - InvestorsObserver
Mon, 08 Nov 2021
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress - Business Wire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
26 |
| Shares Float (M) |
23 |
|
% Held by Insiders
|
13.91 |
|
% Held by Institutions
|
70.06 |
|
Shares Short (K)
|
2,350 |
|
Shares Short P. Month (K)
|
2,500 |
Stock Financials |
|
EPS
|
-7.550 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
9.830 |
|
Profit Margin
|
|
|
Operating Margin
|
-2229.80 |
|
Return on Assets (ttm)
|
-32.4 |
|
Return on Equity (ttm)
|
-75.3 |
|
Qtrly Rev. Growth
|
4.5 |
|
Gross Profit (p.s.)
|
-1.833 |
|
Sales Per Share
|
0.334 |
|
EBITDA (p.s.)
|
-7.403 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-99 |
|
Levered Free Cash Flow (M)
|
-30 |
Stock Valuations |
|
PE Ratio
|
-3.26 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.50 |
|
Price to Sales
|
73.66 |
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2017-11-15 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
